A three-marker signature identifies senescence in human breast cancer exposed to neoadjuvant chemotherapy
Cancer Chemotherapy and Pharmacology · 2023
DOI: 10.1007/s00280-023-04523-w ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2023. Verfasst von Mohammed El-Sadoni und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Microbiology and Forensic Medicine, School of Medicine, The University of Jordan, Amman, 11942, Jordan. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 111 Literaturangaben. Gefördert von: Hashemite University, The University of Jordan, King Saud University.
Themen: Onkologische Pflege
Abstract (Originalsprache)
PURPOSE: Despite the beneficial effects of chemotherapy, therapy-induced senescence (TIS) manifests itself as an undesirable byproduct. Preclinical evidence suggests that tumor cells undergoing TIS can re-emerge as more aggressive divergents and contribute to recurrence, and thus, senolytics were proposed as adjuvant treatment to eliminate senescent tumor cells. However, the identification of TIS in clinical samples is essential for the optimal use of senolytics in cancer therapy. In this study, we aimed to detect and quantify TIS using matched breast cancer samples collected pre- and post-exposure to neoadjuvant chemotherapy (NAC). METHODS: Detection of TIS was based on the change in gene and protein expression levels of three senescence-associated markers (downregulation of Lamin B1 and Ki-67 and upregulation of p16INK4a). RESULTS: Our analysis revealed that 23 of 72 (31%) of tumors had a shift in the protein expression of the three markers after exposure to NAC suggestive of TIS. Gene expression sets of two independent NAC-treated breast cancer samples showed consistent changes in the expression levels of LMNB1, MKI67 and CDKN2A. CONCLUSIONS: Collectively, our study shows a more individualized approach to measure TIS hallmarks in matched breast cancer samples and provides an estimation of the extent of TIS in breast cancer clinically. Results from this work should be complemented with more comprehensive identification approaches of TIS in clinical samples in order to adopt a more careful implementation of senolytics in cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Microbiology and Forensic Medicine, School of Medicine, The University of Jordan, Amman, 11942, Jordan.
- Department of Pharmacology and Public Health, Faculty of Medicine, The Hashemite University, Zarqa, 13133, Jordan.
- Department of Pathology, Royal Medical Services, King Hussein Medical Center, Amman, 11942, Jordan.
- Cell Therapy Center, The University of Jordan, Amman, 11942, Jordan.
- Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
- Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY, 10032, USA.
Förderung
- Hashemite University
- The University of Jordan
- King Saud University
Zitieren
APA
El-Sadoni, M., Shboul, S. A., Alhesa, A., Shahin, N. A., Alsharaiah, E., Ismail, M. A., Ababneh, N. A., Alotaibi, M. R., Azab, B., & Saleh, T. (2023). A three-marker signature identifies senescence in human breast cancer exposed to neoadjuvant chemotherapy. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-023-04523-w
Vancouver
El-Sadoni M, Shboul SA, Alhesa A, Shahin NA, Alsharaiah E, Ismail MA, et al. A three-marker signature identifies senescence in human breast cancer exposed to neoadjuvant chemotherapy. Cancer Chemotherapy and Pharmacology. 2023. doi:10.1007/s00280-023-04523-w
BibTeX
@article{ElSadoni2023,
author = {El-Sadoni, Mohammed and Shboul, Sofian Al and Alhesa, Ahmad and Shahin, Nisreen Abu and Alsharaiah, Elham and Ismail, Mohammad A and Ababneh, Nidaa A and Alotaibi, Moureq R and Azab, Bilal and Saleh, Tareq},
title = {A three-marker signature identifies senescence in human breast cancer exposed to neoadjuvant chemotherapy},
journal = {Cancer Chemotherapy and Pharmacology},
year = {2023},
doi = {10.1007/s00280-023-04523-w}
}
EUVIMED